Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Tempus AI Stock After FDA Clearance for AI Heart Valve Detection

6 October 2026 · By · Wire by Fusion42

Published

6 October 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at simplywall.st →

◆ Verified

Fusion42 · 6 October 2026 · Fusion42 review

Tempus AI received FDA 510(k) clearance for its ECG-MR AI tool that detects moderate or severe mitral regurgitation in elderly patients, expanding its AI portfolio from oncology and genetics into cardiovascular diagnostics.

This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it between 28 Sep 2026 and 6 Oct 2026.

◆ ◆ The Wire takeaway

You should pivot your cardiovascular AI product development to integrate with clinical ECG workflows now that FDA clearance validates AI for heart valve disease detection and opens hospital adoption paths.

◆ Coverage

2 sources · first reported 28 Sep 2026 · latest 6 Oct 2026

◆ Related on Wire

◆ Topics

Healthfda-clearancecardiovascular-aidiagnosticshealthcare-aiclinical-workflows